U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
3372133721BI 836845 in Estrogen Receptor Positive Metastatic Breast CancerRecruitingNo Results AvailableNeoplasmsDrug: Everolimus|Drug: Everolimus|Drug: Everolimus|Drug: Exemestane|Drug: BI 836845|Drug: BI 836845|Drug: Exemestane|Drug: Exemestanehttps://ClinicalTrials.gov/show/NCT02123823
3372233722Quality of Chest Compressions After a Night ShiftCompletedNo Results AvailableCardiac ArrestOther: CPRhttps://ClinicalTrials.gov/show/NCT02123810
3372333723Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic OncologyRecruitingNo Results AvailableLung Cancerhttps://ClinicalTrials.gov/show/NCT02123797
3372433724Biomarkers for the Surgical Treatment of Rotator Cuff TearsRecruitingNo Results AvailableRotator Cuff Tearshttps://ClinicalTrials.gov/show/NCT02123784
3372533725Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori InfectionsRecruitingNo Results AvailableHELICOBACTER PYLORI INFECTIONShttps://ClinicalTrials.gov/show/NCT02123771
3372633726A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNo Results AvailableProstatic Neoplasms|Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug: Abiraterone Acetate|Drug: Prednisone|Drug: JNJ-56021927https://ClinicalTrials.gov/show/NCT02123758
3372733727ivWatch Model 400: Device Validation for Infiltrated TissuesCompletedHas ResultsInfiltration of Peripheral IV TherapyDevice: The ivWatch Model 400https://ClinicalTrials.gov/show/NCT02123745
3372833728Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes MellitusRecruitingNo Results AvailableType 2 Diabetes MellitusDietary Supplement: DbXell|Dietary Supplement: Placebohttps://ClinicalTrials.gov/show/NCT02123732
3372933729Laparoscopic Incisional Hernia Repair in Liver Transplant PatientsCompletedNo Results AvailableHernia Recurrence Post Laparoscopic Incisional Hernia Repair in Liver Transplant Versus Non-transplant Patients.Other: Surgeryhttps://ClinicalTrials.gov/show/NCT02123719
3373033730The Role of Osteopathic Treatment in the Axial Variations of the Lumbar Spine: RCTRecruitingNo Results AvailableLow Back PainOther: Osteopathic manipulative treatment|Other: Sham Therapy|Other: No Interventionhttps://ClinicalTrials.gov/show/NCT02123693
3373133731Chronic Low Back Pain Patients' Expectations Toward PhysiotherapyCompletedNo Results AvailableChronic Low Back Painhttps://ClinicalTrials.gov/show/NCT02123680
3373233732AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)RecruitingNo Results AvailableAsthmahttps://ClinicalTrials.gov/show/NCT02123667
3373333733UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedNo Results AvailableHepatitis C Virus InfectionDrug: Daclatasvir|Drug: Asunaprevir|Drug: DCV 3DAA|Other: Placebo for DCV 3DAA|Other: Placebo for Daclatasvir|Other: Placebo for Asunaprevirhttps://ClinicalTrials.gov/show/NCT02123654
3373433734Physical Activity as Intervention Against Age-related Loss of Muscle Mass and FunctionRecruitingNo Results AvailableMuscle Weakness|Muscle Loss|Sarcopenia|Physical ActivityOther: Heavy resistance training|Other: Moderate intensity training|Other: Controlhttps://ClinicalTrials.gov/show/NCT02123641
3373533735Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot OsteomyelitisCompletedNo Results AvailableDiabetes MellitusDrug: duration of the antibiotic therapyhttps://ClinicalTrials.gov/show/NCT02123628
3373633736ASIS for GAMMAGARD in Primary ImmunodeficiencyNot yet recruitingNo Results AvailablePrimary ImmunodeficiencyDrug: Gadolinium For abdomen|Drug: Gadolinium For abdomen|Drug: Gadolinium For abdomen|Drug: Gadolinium For lower back|Drug: Gadolinium For lower back|Drug: Gadolinium For lower back|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 12|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 24|Drug: Efficacy of Gammagard subcutaneously at Week 36|Drug: Efficacy of Gammagard subcutaneously at Week 36|Drug: Efficacy of Gammagard subcutaneously at Week 36|Drug: Efficacy of Gammagard subcutaneously at Week 36|Drug: Efficacy of Gammagard subcutaneously at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 12|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 24|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Efficacy of Gammagard subdermally at Week 36|Drug: Adverse Reactions of Gammagard subcutaneously at Week 12|Drug: Adverse Reactions of Gammagard subcutaneously at Week 24|Drug: Adverse Reactions of Gammagard subcutaneously at Week 36|Drug: Adverse Reactions of Gammagard subdermally at Week 12|Drug: Adverse Reactions of Gammagard subdermally at Week 24|Drug: Adverse Reactions of Gammagard subdermally at Week 36https://ClinicalTrials.gov/show/NCT02123615
3373733737Core Stabilization for the Treatment of Anterior Knee PainRecruitingNo Results AvailablePatellofemoral Pain SyndromeOther: core stabilization|Other: lower extremity training onlyhttps://ClinicalTrials.gov/show/NCT02123602
3373833738The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill Adults.Not yet recruitingNo Results AvailableSedative Withdrawal DeliriumDrug: Deep sedation(midazolam and fentanyl )|Drug: Deep and daily interruption of sedation(midazolam and fentanyl )|Drug: Light sedation(midazolam and fentanyl )https://ClinicalTrials.gov/show/NCT02123589
3373933739Treatment of Type I Hepatorenal Syndrome (HRS) With PentoxyfyllineRecruitingNo Results AvailableHepatorenal SyndromeDrug: Pentoxyfylline|Drug: Placebo|Drug: AMO Therapyhttps://ClinicalTrials.gov/show/NCT02123576
3374033740Mechanical-chemical Gingival Therapy in Diabetics and/or ObeseCompletedNo Results AvailableGingivitis|Diabetes|ObesityOther: Ultrason Essential oils rinse|Other: Ultrason Placebo rinsehttps://ClinicalTrials.gov/show/NCT02123563
3374133741Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT DetectionRecruitingNo Results AvailableDeep Venous Thrombosishttps://ClinicalTrials.gov/show/NCT02123550
3374233742Treating Foot Drop in People With Multiple Sclerosis Using Electrical StimulationRecruitingNo Results AvailableMultiple Sclerosis|Foot DropDevice: Bioness L300 Foot Drop Systemhttps://ClinicalTrials.gov/show/NCT02123537
3374333743Rivaroxaban Anticoagulation for Superficial Vein ThrombosisRecruitingNo Results AvailableSymptomatic Superficial Vein ThrombosisDrug: Rivaroxaban|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02123524
3374433744Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation TherapyRecruitingNo Results AvailableMucositis|Oral Complications|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Mucoepidermoid Carcinoma ofDrug: acetylcysteine|Other: placebo|Other: quality-of-life assessment|Other: questionnaire administrationhttps://ClinicalTrials.gov/show/NCT02123511
3374533745The Study of Eustachian Tube Dysfunction and Laryngopharyngeal RefluxNot yet recruitingNo Results AvailableEustachian Tube Dysfunction|Laryngopharyngeal RefluxDrug: Omeprazole|Drug: Ranitidine|Drug: Pantoprazole|Procedure: 24-Hour Diagnostic pH-Probe Test|Procedure: Laryngoscopyhttps://ClinicalTrials.gov/show/NCT02123498
3374633746the Antidepressant Effect of rTMS as add-on to ECTRecruitingNo Results AvailableDepressionDevice: Right prefrontal Low frequency (1 hz) rTMS,|Device: Sham-rTMShttps://ClinicalTrials.gov/show/NCT02123485
3374733747A Study of Cephalexin Liquid for Pediatrics in Healthy Adults ParticipantsCompletedHas ResultsHealthy VolunteersDrug: Cephalexinhttps://ClinicalTrials.gov/show/NCT02123472
3374833748A Study of Cephalexin Suspension in Healthy ParticipantsCompletedHas ResultsHealthy VolunteersDrug: Cephalexinhttps://ClinicalTrials.gov/show/NCT02123459
3374933749A Study of Cephalexin Capsules in Healthy ParticipantsCompletedHas ResultsHealthy VolunteersDrug: Cephalexinhttps://ClinicalTrials.gov/show/NCT02123446
3375033750Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV AdultsCompletedNo Results AvailableHIV Infection|Pneumococcal InfectionsBiological: pneumococcal conjugate 13 valent vaccinehttps://ClinicalTrials.gov/show/NCT02123433

* Görseller ve İçerik tekif hakkına sahip olabilir